$129.00
-8.87[-6.43%]
At close: Apr 25
$129.00
0[0.00%]
After Hours: 5:47PM EDT
DexCom
(NASDAQ:DXCM)DexCom Stock (NASDAQ:DXCM), Analyst Ratings, Price Targets, Predictions
DexCom Inc has a consensus price target of $217, established from looking at the 83 latest analyst ratings. The last 3 analyst ratings were released from UBS, Citigroup, and RBC Capital on April 10, 2024, April 3, 2024, and March 12, 2024. With an average price target of $163 between UBS, Citigroup, and RBC Capital, there's an implied 26.36% upside for DexCom Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
UBS
Citigroup
RBC Capital
Raymond James
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for DexCom
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | DXCM | Buy Now | DexCom | $129.00 | 26.36% | UBS | Danielle Antalffy | $153 → $163 | Maintains | Buy | Get Alert |
| 04/03/2024 | DXCM | Buy Now | DexCom | $129.00 | 24.81% | Citigroup | Joanne Wuensch | $148 → $161 | Maintains | Buy | Get Alert |
| 03/12/2024 | DXCM | Buy Now | DexCom | $129.00 | 27.91% | RBC Capital | Shagun Singh | → $165 | Initiates | → Outperform | Get Alert |
| 01/23/2024 | DXCM | Buy Now | DexCom | $129.00 | 17.05% | Raymond James | Jayson Bedford | $147 → $151 | Maintains | Strong Buy | Get Alert |
| 01/03/2024 | DXCM | Buy Now | DexCom | $129.00 | 13.95% | Raymond James | Jayson Bedford | $131 → $147 | Maintains | Strong Buy | Get Alert |
| 12/19/2023 | DXCM | Buy Now | DexCom | $129.00 | 16.28% | Piper Sandler | Matt O'Brien | $135 → $150 | Maintains | Overweight | Get Alert |
| 12/13/2023 | DXCM | Buy Now | DexCom | $129.00 | 5.43% | Wells Fargo | Larry Biegelsen | $110 → $136 | Maintains | Overweight | Get Alert |
| 12/04/2023 | DXCM | Buy Now | DexCom | $129.00 | -5.43% | Morgan Stanley | Patrick Wood | $101 → $122 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | DXCM | Buy Now | DexCom | $129.00 | -21.71% | Morgan Stanley | Patrick Wood | $98 → $101 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | DXCM | Buy Now | DexCom | $129.00 | -22.48% | JP Morgan | Michael Weinstein | $160 → $100 | Maintains | Overweight | Get Alert |
| 10/16/2023 | DXCM | Buy Now | DexCom | $129.00 | -14.73% | Leerink Partners | Mike Kratky | → $110 | Initiates | → Outperform | Get Alert |
| 10/10/2023 | DXCM | Buy Now | DexCom | $129.00 | 12.4% | Stifel | Mathew Blackman | $155 → $145 | Maintains | Buy | Get Alert |
| 09/29/2023 | DXCM | Buy Now | DexCom | $129.00 | -24.03% | Morgan Stanley | Patrick Wood | $131 → $98 | Maintains | Equal-Weight | Get Alert |
| 09/15/2023 | DXCM | Buy Now | DexCom | $129.00 | 1.55% | Raymond James | Jayson Bedford | $154 → $131 | Maintains | Strong Buy | Get Alert |
| 09/06/2023 | DXCM | Buy Now | DexCom | $129.00 | 6.98% | UBS | Danielle Antalffy | $175 → $138 | Maintains | Buy | Get Alert |
| 08/21/2023 | DXCM | Buy Now | DexCom | $129.00 | 0.78% | Baird | Jeff Johnson | $153 → $130 | Maintains | Outperform | Get Alert |
| 07/31/2023 | DXCM | Buy Now | DexCom | $129.00 | 6.98% | Barclays | Matt Miksic | $115 → $138 | Maintains | Equal-Weight | Get Alert |
| 07/28/2023 | DXCM | Buy Now | DexCom | $129.00 | 24.03% | Piper Sandler | Matt O'Brien | $150 → $160 | Maintains | Overweight | Get Alert |
| 07/28/2023 | DXCM | Buy Now | DexCom | $129.00 | 16.28% | Canaccord Genuity | Kyle Rose | $135 → $150 | Maintains | Buy | Get Alert |
FAQ
What is the target price for DexCom (DXCM)?
The latest price target for DexCom (NASDAQ: DXCM) was reported by UBS on April 10, 2024. The analyst firm set a price target for $163.00 expecting DXCM to rise to within 12 months (a possible 26.36% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for DexCom (DXCM)?
The latest analyst rating for DexCom (NASDAQ: DXCM) was provided by UBS, and DexCom maintained their buy rating.
When was the last upgrade for DexCom (DXCM)?
The last upgrade for DexCom Inc happened on April 17, 2023 when Raymond James raised their price target to $138. Raymond James previously had an outperform for DexCom Inc.
When was the last downgrade for DexCom (DXCM)?
The last downgrade for DexCom Inc happened on October 18, 2021 when Guggenheim changed their price target from N/A to N/A for DexCom Inc.
When is the next analyst rating going to be posted or updated for DexCom (DXCM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DexCom, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DexCom was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating DexCom (DXCM) correct?
While ratings are subjective and will change, the latest DexCom (DXCM) rating was a maintained with a price target of $153.00 to $163.00. The current price DexCom (DXCM) is trading at is $129.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.